Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine

Chong Guo; Chaoying Song; Jiali Zhang; Yisong Gao; Yuying Qi; Zongyao Zhao; Chengfu Yuan

doi:10.1016/j.gendis.2020.11.017

您当前的位置：

首页 >

文章列表页 >

Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine

Review article | 更新时间：2022-06-24

- Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
- Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
- Genes & Diseases 2022年9卷第3期
- 作者机构：
  
  1. College of Medical Science, China Three Gorges University,Hubei,Yichang,PR China,443002
  2. Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, China Three Gorges University,Hubei,Yichang,PR China,443002
  3. Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University,Hubei,Yichang,PR China,443002
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.11.017
  中图分类号：
- 纸质出版日期：2022，
  
  网络出版日期：2022-5-1，
扫描看全文
Chong Guo, Chaoying Song, Jiali Zhang, 等. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine[J]. Genes & Diseases, 2022,9(3).

Chong Guo, Chaoying Song, Jiali Zhang, et al. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine[J]. Genes & Diseases, 2022,9(3).
Chong Guo, Chaoying Song, Jiali Zhang, 等. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine[J]. Genes & Diseases, 2022,9(3). DOI： 10.1016/j.gendis.2020.11.017.

Chong Guo, Chaoying Song, Jiali Zhang, et al. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine[J]. Genes & Diseases, 2022,9(3). DOI： 10.1016/j.gendis.2020.11.017.

摘要

Abstract

mong the gynecological cancers

ovarian cancer is the most lethal. Its therapeutic options include a combination of chemotherapy with platinum-based compounds and cytoreductive surgery. Most ovarian cancer patients exhibit an initial response to platinum-based therapy

however

platinum resistance has led to up to 80% of this responsive cohort becoming refractory. Ovarian cancer recurrence and drug resistance to current chemotherapeutic options is a global challenge. Chemo-resistance is a complex phenomenon that involves multiple genes and signal transduction pathways. Therefore

it is important to elucidate on the underlying molecular mechanisms involved in chemo-resistance. This inform decisions regarding therapeutic management and help in the identification of novel and effective drug targets. Studies have documented the individual biomarkers of platinum-resistance in ovarian cancer that are potential therapeutic targets. This review summarizes the molecular mechanisms of platinum resistance in ovarian cancer

novel drug targets

and clinical outcomes.

关键词

Keywords

Clinical outcomesMechanismsMolecular biomarkersOvarian cancerPlatinum resistance

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine

Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development